Afficher la couverture 'Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma. | Crochet, Gilles' en grand format
/5

0 avis

Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma.

Archive ouverte

Crochet, Gilles | Iacoboni, Gloria | Couturier, Audrey | Bachy, Emmanuel | Iraola-Truchuelo, Josu | Gastinne, Thomas | Cartron, Guillaume | Fradon, Tom | Lesne, Bastien | Kwon, Mi | Gounot, Romain | Martínez-Cibrian, Nuria | Castilla-Llorente, Cristina | Abrisqueta, Pau | Guerreiro, Manuel | Sarkozy, Clémentine | Aspa-Cilleruelo, Jose Maria | Camus, Vincent | Guidez, Stéphanie | Chauchet, Adrien | Deconinck, Eric | Bouabdallah, Krimo | Bosch, Francesc | Barba, Pere | Morschhauser, Franck | Roch, Houot

Edité par CCSD ; American Society of Hematology -

International audience. In this retrospective study, CAR T-cells remained effective in relapsed/refractory LBCL patients after prior exposure to bispecific antibodies (BsAbs) targeting different antigens. These results are relevant to clinical practice, particularly given the increasing use of BsAbs in earlier treatment lines.

Suggestions

Du même auteur

Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment

Archive ouverte | Iacoboni, Gloria | CCSD

International audience

Non-Relapse Mortality after CAR T-Cell therapy for Large B-Cell Lymphoma: A LYSA Study from the DESCAR-T Registry

Archive ouverte | Lemoine, Jean | CCSD

International audience. CD19 chimeric antigen receptor (CAR) T cells can induce prolonged remissions and potentially cure a significant proportion of patients with relapsed/refractory large B-cell lymphomas. However...

Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome. A DESCAR-T study

Archive ouverte | Vic, Samuel | CCSD

International audience. Chimeric antigen receptor (CAR) T-cells targeting CD19 have been approved for the treatment of relapse/refractory large B-cell lymphoma. Hematotoxicity is the most frequent CAR T-cell-related...

Chargement des enrichissements...